Novo Nordisk, FDA and Ozempic
Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results